GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Conmed Corp (MEX:CNMD) » Definitions » Cyclically Adjusted Revenue per Share

Conmed (MEX:CNMD) Cyclically Adjusted Revenue per Share : MXN915.40 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Conmed Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Conmed's adjusted revenue per share for the three months ended in Mar. 2025 was MXN210.983. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN915.40 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Conmed's average Cyclically Adjusted Revenue Growth Rate was 4.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 3.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Conmed was 26.30% per year. The lowest was 1.70% per year. And the median was 5.10% per year.

As of today (2025-05-23), Conmed's current stock price is MXN1454.00. Conmed's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was MXN915.40. Conmed's Cyclically Adjusted PS Ratio of today is 1.59.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Conmed was 4.95. The lowest was 1.28. And the median was 2.44.


Conmed Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Conmed's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conmed Cyclically Adjusted Revenue per Share Chart

Conmed Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 569.15 621.51 627.57 613.63 793.71

Conmed Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 857.49 664.54 751.26 793.71 915.40

Competitive Comparison of Conmed's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, Conmed's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Conmed's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Conmed's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Conmed's Cyclically Adjusted PS Ratio falls into.


;
;

Conmed Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Conmed's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=210.983/134.9266*134.9266
=210.983

Current CPI (Mar. 2025) = 134.9266.

Conmed Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 101.962 100.684 136.639
201509 102.476 100.392 137.728
201512 117.839 99.792 159.327
201603 112.521 100.470 151.110
201606 128.029 101.688 169.877
201609 127.832 101.861 169.328
201612 150.182 101.863 198.930
201703 126.058 102.862 165.353
201706 126.648 103.349 165.344
201709 122.423 104.136 158.621
201712 154.382 104.011 200.269
201803 128.479 105.290 164.644
201806 144.970 106.317 183.981
201809 130.093 106.507 164.807
201812 164.468 105.998 209.354
201903 145.901 107.251 183.551
201906 156.007 108.070 194.777
201909 154.791 108.329 192.796
201912 166.968 108.420 207.788
202003 168.920 108.902 209.288
202006 127.602 108.767 158.291
202009 178.550 109.815 219.380
202012 155.854 109.897 191.351
202103 151.576 111.754 183.005
202106 156.457 114.631 184.157
202109 159.176 115.734 185.572
202112 171.327 117.630 196.520
202203 137.249 121.301 152.666
202206 187.288 125.017 202.134
202209 177.906 125.227 191.687
202212 160.442 125.222 172.876
202303 170.677 127.348 180.834
202306 171.278 128.729 179.525
202309 167.421 129.860 173.954
202312 176.216 129.419 183.715
202403 165.725 131.776 169.687
202406 195.591 132.554 199.092
202409 200.435 133.029 203.294
202412 231.574 133.157 234.651
202503 210.983 134.927 210.983

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Conmed  (MEX:CNMD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Conmed's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1454.00/915.40
=1.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Conmed was 4.95. The lowest was 1.28. And the median was 2.44.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Conmed Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Conmed's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Conmed Business Description

Industry
Traded in Other Exchanges
Address
11311 Concept Boulevard, Largo, FL, USA, 33773
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.